Advertisement

Hepatitis C Drug's Price Draws Legislative Attention, Stock Analysts Sanguine — Physician’s First Watch

Medical News |
March 24, 2014

Hepatitis C Drug's Price Draws Legislative Attention, Stock Analysts Sanguine

By Joe Elia

Sovaldi (sofosbuvir), which received FDA approval last December to treat hepatitis C, costs an even $1000 per pill — or $84,000 for a 12-week course of treatment. That has legislators calling for the manufacturer to explain the price.

In a March 20 letter to Gilead Science's CEO, three members of the House Committee on Energy and Commerce write that, because hepatitis C is prevalent in low-income patients, "the affordability problems are likely to be particularly acute for state Medicaid programs and those patients served by these programs."

They request that Gilead explain how it arrived at the price, reminding the company of the value afforded by the FDA's priority review.

The New York Times reports that the letter sent Gilead's stock price down almost 5% on Friday. However, it quoted a Deutsche Bank analyst: "We just look at this letter as a little bit of noise."

Reader Comments (1)

John W Cooper Physician, Family Medicine/General Practice, Novato, CA

And they want to screen nearly everyone for Hep C?

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement